Multi-omics analysis reveals CLIC3 as a key biomarker in triple-negative breast cancer, indicating its potential as a therapeutic target.
CLIC3 is a TNBC-specific prognostic biomarker and therapeutic target. Its inhibition impedes TNBC aggressiveness, providing a foundation for targeted therapy development.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: